Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

Literature DB >> 26056030

Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

Abstract

Aflibercept (Eylea(®)) is an anti-vascular endothelial growth factor agent indicated for intravitreal use in the treatment of diabetic macular oedema. In patients with diabetic macular oedema, significantly greater improvements from baseline to week 52 in visual acuity were seen with intravitreal aflibercept versus macular laser photocoagulation in the phase III VISTA-DME and VIVID-DME trials, and versus intravitreal bevacizumab or ranibizumab in those with worse visual acuity at baseline (i.e. Early Treatment Diabetic Retinopathy Study letter score of <69) in the phase III PROTOCOL-T trial. Intravitreal aflibercept was generally well tolerated in patients with diabetic macular oedema. In conclusion, intravitreal aflibercept is an important new treatment for diabetic macular oedema.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2015 PMID： 26056030 DOI： 10.1007/s40265-015-0421-y

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

33 in total

1. Angiogenic pathways in diabetic retinopathy.

Authors: Lloyd Paul Aiello
Journal: N Engl J Med Date: 2005-08-25 Impact factor: 91.245

2. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

Authors: P Carmeliet; L Moons; A Luttun; V Vincenti; V Compernolle; M De Mol; Y Wu; F Bono; L Devy; H Beck; D Scholz; T Acker; T DiPalma; M Dewerchin; A Noel; I Stalmans; A Barra; S Blacher; T VandenDriessche; A Ponten; U Eriksson; K H Plate; J M Foidart; W Schaper; D S Charnock-Jones; D J Hicklin; J M Herbert; D Collen; M G Persico
Journal: Nat Med Date: 2001-05 Impact factor: 53.440

3. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept.

Authors: Victor H Gonzalez; David S Boyer; Ursula Schmidt-Erfurth; Jeffrey S Heier; Carmelina Gordon; Matthew S Benz; Dennis M Marcus; Nelson R Sabates; Robert Vitti; Husain Kazmi; Alyson J Berliner; Yuhwen Soo; Xiaoping Zhu; Hadi Moini; Oliver Zeitz; Rupert Sandbrink; Diana V Do
Journal: Retina Date: 2015-04 Impact factor: 4.256

4. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors: Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal: Ophthalmology Date: 2012-02-11 Impact factor: 12.079

Review 5. Aflibercept for intravitreal injection: in neovascular age-related macular degeneration.

Authors: James E Frampton
Journal: Drugs Aging Date: 2012-10 Impact factor: 3.923

6. VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors: Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal: Proc Natl Acad Sci U S A Date: 2002-08-12 Impact factor: 11.205

Review 7. Overview of epidemiologic studies of diabetic retinopathy.

Authors: Barbara Eden Kobrin Klein
Journal: Ophthalmic Epidemiol Date: 2007 Jul-Aug Impact factor: 1.648

8. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.

Authors: Sven Schnichels; Ulrike Hagemann; Kai Januschowski; Johanna Hofmann; Karl-Ulrich Bartz-Schmidt; Peter Szurman; Martin S Spitzer; Sabine Aisenbrey
Journal: Br J Ophthalmol Date: 2013-05-17 Impact factor: 4.638

Review 9. Intravitreal aflibercept (Eylea(®)): a review of its use in patients with macular oedema secondary to central retinal vein occlusion.

Authors: Lily P H Yang; Kate McKeage
Journal: Drugs Aging Date: 2014-05 Impact factor: 3.923

10. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Authors: Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand
Journal: Angiogenesis Date: 2012-06 Impact factor: 9.596

4 in total